Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging technique could reveal how brain tumors hide from the immune system

NCT ID NCT05267509

Knowledge-focused Sponsor: Istituto Oncologico Veneto IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how aggressive brain tumors (gliomas) suppress the immune system. Researchers will use special MRI and PET scans to track immune cells and iron levels in the tumor. The goal is to find better ways to measure immune suppression, which could help develop new treatments. The study involves 31 adults with malignant glioma.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify new ways to measure immune suppression in brain tumors, potentially guiding future treatments.
What could go wrong
This is a small, early-stage observational study (31 participants) that does not test a treatment. It may not lead to direct patient benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

31 people

The number who actually took part.

Started

Feb 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with histologic confirmation of malignant glioma

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients with histologic confirmation of malignant glioma * Patients must be age \>= 18 years * Patients must be able to obtain an MRI scan with gadolinium contrast * Patients must sign informed consent indicating that they are aware of the investigational nature of this study:

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioma, malignant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioma, malignant

Contacts and locations

Locations

  • University Hospital

    Florence, Italy

  • University Hospital

    Padova, 325128, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.